Stocks Health care MPLT
NASDAQ · Health careMapLight Therapeutics, Inc. (MPLT)
It posted a net loss of $229.8M. In fiscal 2025 capital spending exceeded operating cash flow by $138.6M. At June 30, 2026 it held $71.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about MapLight Therapeutics, Inc.
- Net worth
- MapLight Therapeutics, Inc. has a market value (market cap) of $317.8M at the latest share price, and shareholders' equity of $348.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $138.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- MapLight Therapeutics, Inc.'s next report was expected around October 15, 2026 and is not on file with the SEC yet.
What MapLight Therapeutics, Inc. does
MapLight Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MPLT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$161.2M | -$18.56 | -$138.6M |
| 2025 | n/a | -$77.6M | -$105.38 | -$79.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What MapLight Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 9, 2026IPO registration S-1
- August 20, 2026Passive stake (5% or more) SCHEDULE 13G
- August 18, 2026Activist stake changed SCHEDULE 13D/A
- August 13, 2026
- August 13, 2026
- August 3, 2026Activist stake changed SCHEDULE 13D/A
- July 31, 2026Activist stake changed SCHEDULE 13D/A
- July 27, 2026
- June 24, 2026
Insider trades
What the people running MapLight Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $50.1M and sold $1.3M worth of shares in the last 90 days. 15% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Kroeger Christopher A.Chief Executive Officer, Director | Sold | 73,691 | $595.4K |
| October 15, 2026 | Gillis JonathanCAO and Interim CFO | Sold | 10,167 | $82.1K |
| October 15, 2026 | Lillie James WoodruffChief Scientific Officer | Sold | 11,513 | $93K |
| October 15, 2026 | Hanson KristopherGeneral Counsel | Sold | 9,020 | $72.9K |
| October 15, 2026 | Foff Erin PennockChief Medical Officer | Sold | 15,355 | $124.1K |
| October 15, 2026 | Kreitzer AnatolChief Discovery Officer | Sold | 12,248 | $96K |
| September 16, 2026 | Hanson KristopherGeneral Counsel | Soldpre-planned (10b5-1) | 16,509 | $192.7K |
| August 17, 2026 | Kroeger Christopher A.Chief Executive Officer, Director | Received as pay | 23,145 | - |
Who owns MPLT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Catalyst4, Inc.13D, may seek influence with 3 related filers | 49.9% | August 18, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 7.4% | May 15, 2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A.13G, passive with 1 related filers | 7.1% | February 17, 2026 |
| Nan Fung Group Holdings Limited13G, passive with 9 related filers | 5.5% | August 20, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 106 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Novo Holdings A/S | 3,686,622 | 0 |
| Fcpm III Services B.V. | 3,226,400 | 0 |
| Goldman Sachs Group Inc | 1,948,312 | -46,561 |
| BlackRock, Inc. | 1,025,134 | -314,597 |
| Nan Fung Group Holdings Ltd | 971,253 | 0 |
| 5AM Venture Management, LLC | 950,011 | 0 |
| Sanofi | 912,041 | 0 |
| State Street Corp | 852,150 | +513,034 |
| Fmr LLC | 823,556 | +619,055 |
| Vanguard Capital Management LLC | 784,150 | +64,330 |
| Blue Owl Capital Holdings LP | 729,929 | -276,000 |
| Paradigm Biocapital Advisors LP | 685,852 | new |
| Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | -1 |
| Velan Capital Investment Management LP | 492,893 | 0 |
| Siren, L.L.C. | 450,000 | 0 |
| Capital World Investors | 415,730 | new |
| Geode Capital Management, LLC | 402,051 | -79,150 |
| Baker Bros. Advisors LP | 364,705 | 0 |
| DAFNA Capital Management LLC | 171,006 | 0 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 170,862 | -96,884 |
Insiders
15 insiders reported holding 28,304,336 shares in total, about $206.1M at the last price.
| Holder | Shares |
|---|---|
| Catalyst4, Inc.10% owner | 25,306,68925,306,689 held indirectly |
| Kroeger Christopher A.Chief Executive Officer, Director | 1,195,909 |
| Setia VishwasChief Financial Officer | 356,256 |
| Malenka Robert C.Director | 316,466 |
| Foff Erin PennockChief Medical Officer | 296,906 |
| Lillie James WoodruffChief Scientific Officer | 198,597 |
| Kreitzer AnatolChief Discovery Officer | 168,678 |
| Gillis JonathanCAO and Interim CFO | 142,315 |
| Hanson KristopherGeneral Counsel | 128,024 |
| Garnett Timothy JohnDirector | 67,58114,124 held indirectly |
Questions about MPLT
What does MapLight Therapeutics, Inc. do?
MapLight Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as MPLT. Its shares trade on NASDAQ under the ticker MPLT.
What is MapLight Therapeutics, Inc.'s net worth?
MapLight Therapeutics, Inc. has a market value (market cap) of $317.8M at the latest share price, and shareholders' equity of $348.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is MapLight Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $229.8M.
When did MapLight Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 16, 2026.
When is MapLight Therapeutics, Inc.'s next earnings report?
MapLight Therapeutics, Inc.'s next report was expected around October 15, 2026 and is not on file with the SEC yet.
Similar companies
Compare MPLT with
Follow MPLT
Get an email when MapLight Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values MapLight Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.